Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Mood disorders (depression, bipolar disorders) are prevalent and disabling. They are also highly co-morbid with other psychiatric disorders. Currently there are no objective measures, such as blood tests, used in clinical practice, and available treatments do not work in everybody. The development of blood tests, as well as matching of patients with existing and new treatments, in a precise, personalized and preventive fashion, would make a significant difference at an individual and societal level. Early pilot studies by us to discover blood biomarkers for mood state were promising [1], and validated by others [2]. Recent work by us has identified blood gene expression biomarkers that track suicidality, a tragic behavioral outcome of mood disorders, using powerful longitudinal within-subject designs, validated them in suicide completers, and tested them in independent cohorts for ability to assess state (suicidal ideation), and ability to predict trait (future hospitalizations for suicidality) [3–6]. These studies showed good reproducibility with subsequent independent genetic studies [7]. More recently, we have conducted such studies also for pain [8], for stress disorders [9], and for memory/Alzheimer’s Disease [10]. We endeavored to use a similar comprehensive approach to identify more definitive biomarkers for mood disorders, that are transdiagnostic, by studying mood in psychiatric disorders patients. First, we used a longitudinal within-subject design and whole-genome gene expression approach to discover biomarkers which track mood state in subjects who had diametric changes in mood state from low to high, from visit to visit, as measured by a simple visual analog scale that we had previously developed (SMS-7). Second, we prioritized these biomarkers using a convergent functional genomics (CFG) approach encompassing in a comprehensive fashion prior published evidence in the field. Third, we validated the biomarkers in an independent cohort of subjects with clinically severe depression (as measured by Hamilton Depression Scale, (HAMD)) and with clinically severe mania (as measured by the Young Mania Rating Scale (YMRS)). Adding the scores from the first three steps into an overall convergent functional evidence (CFE) score, we ended up with 26 top candidate blood gene expression biomarkers that had a CFE score as good as or better than SLC6A4, an empirical finding which we used as a de facto positive control and cutoff. Notably, there was among them an enrichment in genes involved in circadian mechanisms. We further analyzed the biological pathways and networks for the top candidate biomarkers, showing that circadian, neurotrophic, and cell differentiation functions are involved, along with serotonergic and glutamatergic signaling, supporting a view of mood as reflecting energy, activity and growth. Fourth, we tested in independent cohorts of psychiatric patients the ability of each of these 26 top candidate biomarkers to assess state (mood (SMS-7), depression (HAMD), mania (YMRS)), and to predict clinical course (future hospitalizations for depression, future hospitalizations for mania). We conducted our analyses across all patients, as well as personalized by gender and diagnosis, showing increased accuracy with the personalized approach, particularly in women. Again, using SLC6A4 as the cutoff, twelve top biomarkers had the strongest overall evidence for tracking and predicting depression after all four steps: NRG1, DOCK10, GLS, PRPS1, TMEM161B, GLO1, FANCF, HNRNPDL, CD47, OLFM1, SMAD7, and SLC6A4. Of them, six had the strongest overall evidence for tracking and predicting both depression and mania, hence bipolar mood disorders. There were also two biomarkers (RLP3 and SLC6A4) with the strongest overall evidence for mania. These panels of biomarkers have practical implications for distinguishing between depression and bipolar disorder. Next, we evaluated the evidence for our top biomarkers being targets of existing psychiatric drugs, which permits matching patients to medications in a targeted fashion, and the measuring of response to treatment. We also used the biomarker signatures to bioinformatically identify new/repurposed candidate drugs. Top drugs of interest as potential new antidepressants were pindolol, ciprofibrate, pioglitazone and adiphenine, as well as the natural compounds asiaticoside and chlorogenic acid. The last 3 had also been identified by our previous suicidality studies. Finally, we provide an example of how a report to doctors would look for a patient with depression, based on the panel of top biomarkers (12 for depression and bipolar, one for mania), with an objective depression score, risk for future depression, and risk for bipolar switching, as well as personalized lists of targeted prioritized existing psychiatric medications and new potential medications. Overall, our studies provide objective assessments, targeted therapeutics, and monitoring of response to treatment, that enable precision medicine for mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4 Example of report for physicians. Using the panel of the top biomarkers BioM12 + 1: Depression (n = 12 genes), as well as RPL3 for mania risk. This subject (Phchp328) was previously described by us in a suicidality biomarker study (Levey et al. [5]), as high risk for suicide, and died by suicide a year after completing our study. No information was provided to her clinicians by us at that time due to anonymity and privacy rules in research studies. The raw expression values of the biomarkers were Z-scored by gender and diagnosis. The Z-scored expression value of each increased biomarker was compared to the average value for the biomarker in the severely depressed group (HAMD ≥ 22), and the average value of the non-depressed group (HAMD ≤ 7), resulting in scores of 1 or 0, respectively, and 0.5 if it was in between. The reverse was done for decreased biomarkers. The “digitized” biomarkers were then added into a polygenic risk score. The subject had a BioM12 polygenic depression score of 88.46, being at the 90% of the 794 subjects in our database. Three out of the three biomarkers for future risk for depression hospitalizations (NRG1, PRPS1, SMAD7) had a score of 1 in this patient (***). More than 50% of the 6 bipolar biomarkers that are part of the BioM12 (Table 3A and B) (*), as well as the mania marker RPL3 (Table 3C) (*), had a score of 1 in this patient, resulting in increased risk for bipolar switching (**). This subject’s clinical diagnosis was major depressive disorder (MDD), but it is likely she had bipolar disorder. The “digitized” biomarkers were also used for matching with existing psychiatric medications. Biomarkers were matched based on our CFG databases with existing psychiatric medications that had effects on gene expression opposite to depression, in the direction of high mood. Each medication matched to a biomarker got a score of 1 that was then multiplied with the biomarker score of 1, 0.5 or 0. The scores for the medications were added, and medications prioritized by this score. In addition, the signature of the biomarkers in the panel that had a score of 1, and their direction of change, was used to interrogate the CMAP and LINCS databases for new repurposed medications that would treat depression in this patient.](https://figures.cochat.ai/paper-figures/3f230e7d4a454dfbae45c3d70c211064/precision-medicine-for-mood-disorders-objective-assessment-risk-prediction-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, blood testing has identified genes (e.g., NRG1 which is involved in regulation of proliferation, survival, and differentiation of many cell types including neurons and epithelial cells207), proteins (e.g. CD47 which is implicated in neuroinflammatory cascades208), and proinflammatory markers (IL-1β, IL-6)209-211 that are associated with depression.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [211]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent study also implicates the significance of asiaticoside, among other candidate drugs, as an emerging anti‐depressant. 77”
From Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review (2023) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Howard, D. M., Adams, M. J., Clarke, T.-K., Hafferty, J. D., Gibson, J., Shirali, M., Coleman, J. R. I., Hagenaars, S. P., Ward, J., Wigmore, E. M., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0326-7 · Cited by 2,565
Genome-wide association study identifies 30 loci associated with bipolar disorder
eQTLGen Consortium, Stahl, E. A., BIOS Consortium, the Bipolar Disorder Working Group of the Psychiatric Genomics Consortium, Breen, G., Forstner, A. J., McQuillin, A., Ripke, S., Trubetskoy, V., Mattheisen, M., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0397-8 · Cited by 1,519
Personal omics profiling reveals dynamic molecular and medical phenotypes
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.009 · Cited by 1,291
Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · PubMed · Cited by 943
Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0209 · Cited by 922
Sex-specific transcriptional signatures in human depression
Labonté, B., Engmann, O., Purushothaman, I., Menard, C., Wang, J., Tan, C., Scarpa, J. R., Moy, G., Loh, Y.-H. E., Cahill, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4386 · Cited by 748
The transcriptional landscape of age in human peripheral blood
Peters, M. J., Joehanes, R., Pilling, L. C., Schurmann, C., Conneely, K. N., Powell, J., Reinmaa, E., Sutphin, G. L., Zhernakova, A., Schramm, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9570 · Cited by 725 · cited 2×
“Interestingly, it is increased in expression in blood in our previous biomarker studies on suicidality [6], stress [9], pain [8], and psychosis [17], as well as increased in expression in blood in aging [18], all co-morbidities associated with depression.”
BackgroundA Genome-wide RNAi Screen for Modifiers of the Circadian Clock in Human Cells
Zhang, E. E., Liu, A. C., Hirota, T., Miraglia, L. J., Welch, G., Pongsawakul, P. Y., Liu, X., Atwood, A., Huss, J. W., Janes, J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.08.031 · Cited by 431
Bagot, R. C., Cates, H. M., Purushothaman, I., Lorsch, Z. S., Walker, D. M., Wang, J., Huang, X., Schlüter, O. M., Maze, I., Peña, C. J., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.015 · Cited by 333 · cited 1×
“DOCK10 (dedicator of cytokinesis 10) has some prior human evidence in human blood from bipolars [20], and is decreased in expression in brain in an animal model of depression [21].”
Background
Cited by
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review
Bandopadhyay, S., Mandal, S., Ghorai, M., Jha, N. K., Kumar, M., Radha, Ghosh, A., Proćków, J., Pérez de la Lastra, J. M., & Dey, A. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17635 · Cited by 220
McCarthy, M. J., Gottlieb, J. F., Gonzalez, R., McClung, C. A., Alloy, L. B., Cain, S., Dulcis, D., Etain, B., Frey, B. N., Garbazza, C., et al. (2022) · Bipolar Disorders · doi:10.1111/bdi.13165 · Cited by 136
Goetzl, E. J., Wolkowitz, O. M., Srihari, V. H., Reus, V. I., Goetzl, L. M., Kapogiannis, D., Heninger, G. R., & Mellon, S. H. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01268-x · Cited by 120
Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
Cacabelos, R., Naidoo, V., Corzo, L., Cacabelos, N., & Carril, J. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413302 · Cited by 107
Metadata
- Authors
- Le-Niculescu, H., Roseberry, K., Gill, S. S., Levey, D. F., Phalen, P. L., Mullen, J., Williams, A., Bhairo, S., Voegtline, T., Davis, H., Shekhar, A., Kurian, S. M., & Niculescu, A. B.
- Affiliations
- Indiana University School of Medicine (US)
- Yale University (US)
- University of Maryland, Baltimore (US)
- University of Pittsburgh (US)
- Scripps Health (US)
- Corresponding author
- Niculescu, A. B.
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-04-08
- Volume
- 26
- Issue
- 7
- Pages
- 2776-2804
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8505261
- OpenAlex
- W3139996120
- Cited by
- 94
- References
- 38
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 18 · 2023: 23 · 2022: 19 · 2021: 10
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs (I01 CX000139, I01 CX002094)
- National Institutes of Health (1dp2od007363-01)
- National Institute of Mental Health (R01MH117431)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mood disorders, depression, bipolar disorder, circadian genes, serotonin transporter, risk prediction, pharmacogenomics, drug repurposing, suicide risk, transdiagnostic biomarkers, personalized medicine, within-subjects design, circadian rhythm, neuroinflammation
- MeSH terms
- Humans, Pharmacogenetics, Reproducibility of Results, Risk Assessment, Mood Disorders, Precision Medicine, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. https://app.cochat.ai/papers/10.1038/s41380-021-01061-w
- The paper
- Le-Niculescu, H., Roseberry, K., Gill, S. S., Levey, D. F., Phalen, P. L., Mullen, J., Williams, A., Bhairo, S., Voegtline, T., Davis, H., Shekhar, A., Kurian, S. M., & Niculescu, A. B. (2021). Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01061-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.